Form 4: Acumen Pharmaceuticals Director Laura Stoppel Receives Equity Grants, Disclaims Personal Beneficial Ownership for RA Capital Funds

Acumen Pharmaceuticals, Inc. Director Laura Stoppel was granted 12,800 restricted stock units and options to purchase 19,500 shares of common stock, though she disclaims personal beneficial ownership as these are held for the benefit of RA Capital Management funds.

Summary

• Laura Stoppel, a Director of Acumen Pharmaceuticals, Inc. (ABOS), was granted equity awards on June 4, 2025.
• The awards include 12,800 Restricted Stock Units (RSUs) and options to purchase 19,500 shares of common stock.
• The RSUs were granted at a price of $0, representing a contingent right to receive one share of common stock per RSU.
• The stock options have an exercise price of $1.07 per share and an expiration date of June 4, 2035.
• Both the RSUs and stock options will vest in full on the earlier of the first anniversary of the grant date or the 2026 annual stockholder meeting, contingent on Ms. Stoppel's continuous service.
• Ms. Stoppel holds these awards for the benefit of R.A. Capital Healthcare Fund, L.P., R.A. Capital Nexus Fund II, L.P., and a separately managed account, all managed by RA Capital Management, L.P.
• She is obligated to transfer any net cash or stock received from these awards to RA Capital Management, L.P., which will offset advisory fees owed by the aforementioned funds.
• Consequently, Ms. Stoppel disclaims beneficial ownership of these RSUs, options, and the underlying common stock.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is a routine corporate action. The grants are substantial in number, but the director disclaims personal beneficial ownership, indicating these are held for the benefit of RA Capital Management funds. This is an expected compensation mechanism for a director representing an institutional investor.

Positives

• The company is granting equity awards to a director, which can align interests with shareholders (though in this specific case, the beneficial ownership is disclaimed by the individual).
• The grants are part of a compensation structure for a director associated with a significant investment firm (RA Capital Management).

Negatives

• The director disclaims beneficial ownership, meaning these grants do not directly increase her personal stake or align her personal financial interests with the company's stock performance in the traditional sense; instead, they benefit RA Capital Management's funds.

Future Outlook

The RSUs and stock options are subject to vesting on the earlier of the first anniversary of the grant date (June 4, 2026) or the 2026 annual stockholder meeting, contingent on continuous service.

Management Comments

• "Represents a restricted stock unit ('RSU') award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."
• "Under the Reporting Person's arrangement with RA Capital Management, L.P. (the 'Adviser'), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the 'Fund'), R.A. Capital Nexus Fund II, L.P. (the 'Nexus Fund II') and a separately managed account (the 'Account'). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."
• "The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."

Industry Context

This Form 4 filing details an equity grant to a director of a pharmaceutical company. Such grants are a common form of compensation in the biotech and pharmaceutical industries, often used to attract and retain talent, and to align the interests of directors and executives with long-term company performance. The involvement of RA Capital Management, a prominent healthcare investment firm, suggests a strategic relationship, where the director's role may also serve the interests of the funds managed by RA Capital.

Comparison to Industry Standards

• Equity grants to directors are standard practice across industries, including pharmaceuticals, to incentivize performance and align interests.
• The vesting schedule (one year or next annual meeting) is a common short-to-medium term vesting period for director equity.
• The disclaimer of beneficial ownership, where the director holds the equity for the benefit of an investment fund, is a specific arrangement often seen when a director is appointed as a representative of a significant institutional investor (like a venture capital or hedge fund). This is not a standard individual compensation structure but rather a mechanism for the fund to receive equity compensation related to its representative's board service.

Related Party Transactions

• The arrangement where Laura Stoppel holds the RSUs and stock options for the benefit of RA Capital Management, L.P.'s funds (R.A. Capital Healthcare Fund, L.P., R.A. Capital Nexus Fund II, L.P., and a separately managed account) and is obligated to turn over net proceeds to the Adviser, constitutes a related party transaction. This offsets advisory fees owed by the funds to the Adviser.

Stakeholder Impact

• Shareholders: The issuance of RSUs and stock options will lead to a slight dilution upon vesting and exercise. However, it also signifies continued board representation from a significant institutional investor (RA Capital Management), which could be viewed positively for governance and strategic oversight.
• RA Capital Management Funds: These funds are the ultimate beneficiaries of the equity grants, which will contribute to their investment returns in Acumen Pharmaceuticals, Inc.
• Laura Stoppel: While she holds the awards, she disclaims personal beneficial ownership, meaning the direct financial benefit accrues to RA Capital Management, L.P. and its managed funds, rather than her personal wealth. Her compensation for board service would be separate.

Next Steps

• Vesting of 12,800 Restricted Stock Units (RSUs) on the earlier of June 4, 2026, or the 2026 annual stockholder meeting.
• Vesting of options to purchase 19,500 shares on the earlier of June 4, 2026, or the 2026 annual stockholder meeting.
• Potential exercise of stock options by RA Capital Management funds before June 4, 2035.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Laura Stoppel, RA Capital Management, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Insider Transaction